What caused the GNCA stock drop to $0.0001?

The drop reflects long-term decline after a Chapter 11 filing, thin trading liquidity, and uncertainty around Genocea's clinical programs. Market reactions and potential delisting risk amplified the fall in GNCA stock.

Is GNCA stock a buy after the 97% drop?

Given cash per share **$0.54**, negative cash flow, restructuring history, and model forecasts near zero, Meyka AI classifies GNCA stock as high risk. Investors should await clarity from filings and asset-sale updates.

What are the key financial metrics to watch for GNCA stock?

Monitor cash per share **$0.54**, operating cash flow per share **-0.66**, book value per share **$0.39**, and any updates to enterprise value and restructuring terms that affect shareholder outcomes.

How does sector performance affect GNCA stock?

Biotechnology sector moves and peer trial results can shift risk appetite for GNCA stock. Positive funding or M&A in biotech can create limited upside; negative sector sentiment increases delisting and liquidity risks.

US Stocks

GNCA stock down 97% to $0.0001 on NASDAQ: Key metrics and what to watch next

ByDanny Kontos February 18, 2026February 18, 2026

GNCA stock closed the market on 17 Feb 2026 at $0.0001, down -97.44% on the day on the NASDAQ in the United States. Trading volume for the session was 30,268 shares versus a 50-day average of 80,568, after the stock opened at $0.0007 and hit an intraday high and low of $0.0001. The plunge follows a long decline from a 52-week high of $1.45, leaving liquidity thin and the float effectively near zero. Investors should watch cash per share, enterprise value metrics, and any Chapter 11 follow-up that could drive further GNCA stock moves.